Related references
Note: Only part of the references are listed.Omalizumab and the risk of malignancy: Results from a pooled analysis
William Busse et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2012)
Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE
Philip J. Lowe et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Omalizumab: Anti-IgE Therapy in Allergy
Matthias Volkmar Kopp
CURRENT ALLERGY AND ASTHMA REPORTS (2011)
After 6 years with Xolair; a 3-year withdrawal follow-up
A. Nopp et al.
ALLERGY (2010)
Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously
Wolfgang Kamin et al.
PEDIATRIC ALLERGY AND IMMUNOLOGY (2010)
Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma
M. V. Kopp et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2009)
Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma
Bob Lanier et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2009)
CD-sens and clinical changes during withdrawal of Xolair after 6 years of treatment
A. Nopp et al.
ALLERGY (2007)
Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma:: 10-year follow-up on the PAT study
L. Jacobsen et al.
ALLERGY (2007)
Efficacy of Omalizumab using extended dose intervals
R. M. Katz et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2007)
Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR
AM Vignola et al.
ALLERGY (2004)
Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis
J Kuehr et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2002)
Effect of omalizumab on symptoms of seasonal allergic rhinitis - A randomized controlled trial
TB Casale et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
W Busse et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2001)
Share Paper
